NCT02959892View on ClinicalTrials.gov

A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS)

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 5, 2016

Primary Completion Date

May 30, 2017

Study Completion Date

August 23, 2017

Conditions
Healthy Volunteers
Interventions
DRUG

Amphetamine

Amphetamine tablets.

DRUG

TAK -041

TAK-041 oral suspension.

DRUG

[11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO)

\[11C\]PHNO injection.

Trial Locations (1)

NW107EW

Hammersmith Medicines Research, London

Sponsors

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

Neurocrine Biosciences

INDUSTRY